A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML [ 2013 - 2017 ]

Research Grant

Researchers: A/Pr Andrew Wei (Principal investigator) ,  A/Pr Mark Levis ,  Prof Andrew Roberts ,  Prof Kenneth Bradstock ,  Prof Michael Murray

Brief description Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients with this poor risk blood cancer.

Funding Amount $AUD 1,169,549.62

Funding Scheme Project Grants

Notes Standard Project Grant